Wang Xiying, Sawada Tomoko, Sawada Osamu, Saishin Yoshitsugu, Liu Ping, Ohji Masahito
Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan; Key Laboratory of Harbin Medical University Eye Center, Eye Hospital, First Affiliated Hospital, Harbin Medical University, Harbin, P.R. China.
Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan.
Am J Ophthalmol. 2014 Oct;158(4):738-744.e1. doi: 10.1016/j.ajo.2014.06.009. Epub 2014 Jun 25.
To evaluate serum and plasma vascular endothelial growth factor (VEGF) concentrations in neovascular age-related macular degeneration patients treated bimonthly with an intravitreal injection of aflibercept or ranibizumab.
Prospective, interventional case series.
This study includes 17 eyes of 17 patients treated with 2 mg aflibercept (the aflibercept group), 15 eyes of 15 patients treated with 0.5 mg ranibizumab (the ranibizumab group), and 12 patients with cataract (the control group). Serum and plasma VEGF concentrations were quantified using the enzyme-linked immunosorbent assay.
At baseline, mean serum VEGF concentration (in picograms per milliliter) did not differ significantly among the 3 groups (P = .99). In the aflibercept group, it was 28.3 pg/mL at baseline, decreased to below the detectable limit at 1 week (P < .0001), increased to 11.7 pg/mL at 1 month, which was still significantly less than the baseline level (P < .001), and returned to 23.9 pg/mL (P = .35) at 2 months. In the ranibizumab group, there were no significant differences. At baseline, mean plasma VEGF concentration did not differ significantly among the 3 groups (P = .64). In the aflibercept group, it was 16.2 at baseline, decreased to less than the detectable limit at 1 week (P < .01) and at 1 month (P < .05), and returned to 13.6 pg/mL at 2 months (P = .73). In the ranibizumab group, there were no significant differences.
Aflibercept significantly decreased serum and plasma VEGF concentrations 1 month after injection; however, ranibizumab had no significant effect on either serum or plasma VEGF level.
评估每两个月接受一次玻璃体内注射阿柏西普或雷珠单抗治疗的新生血管性年龄相关性黄斑变性患者的血清和血浆血管内皮生长因子（VEGF）浓度。
前瞻性干预性病例系列研究。
本研究纳入17例接受2mg阿柏西普治疗的患者的17只眼（阿柏西普组）、15例接受0.5mg雷珠单抗治疗的患者的15只眼（雷珠单抗组）以及12例白内障患者（对照组）。采用酶联免疫吸附测定法对血清和血浆VEGF浓度进行定量分析。
基线时，三组患者的平均血清VEGF浓度（皮克/毫升）差异无统计学意义（P = 0.99）。在阿柏西普组，基线时为28.3 pg/mL，1周时降至检测限以下（P < 0.0001），1个月时升至11.7 pg/mL，仍显著低于基线水平（P < 0.001），2个月时恢复至23.9 pg/mL（P = 0.35）。在雷珠单抗组，差异无统计学意义。基线时，三组患者的平均血浆VEGF浓度差异无统计学意义（P = 0.64）。在阿柏西普组，基线时为16.2，1周时降至检测限以下（P < 0.01），1个月时仍低于检测限（P < 0.05），2个月时恢复至13.6 pg/mL（P = 0.73）。在雷珠单抗组，差异无统计学意义。
注射阿柏西普1个月后可显著降低血清和血浆VEGF浓度；然而，雷珠单抗对血清或血浆VEGF水平均无显著影响。
